Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB:SNTID) today announced financial results for the three months ended September 30, 2013 (“First Quarter 2014”).
Fiscal First Quarter and Recent Highlights
•The Company began dosing patients in the third cohort at a four-fold increase in the dose level from 0.05 mg/kg to 0.2 mg/kg in its Phase 1b/2a clinical trial for the treatment of multiple myeloma, diffuse large B-cell lymphoma and mantle cell lymphoma. At this does level, the Company has seen efficacy in the preclinical cancer models in mice.
Help employers find you! Check out all the jobs and post your resume.
